title: [Hepatitis-associated aplastic anaemia: clinical characteristics and immunosuppressive therapy outcomes].
abstract: OBJECTIVE
  To analyze the clinical characteristics and to evaluate immunosuppressive therapy (IST) response and survival in hepatitis-associated aplastic anemia (HAAA).
  
  
  METHODS
  We retrospectively analyzed clinical characteristics, IST response, long-term survival and clonal evolution in 41 HAAA patients, and compared those with age and bone marrow failure matched idiopathic aplastic anemia (IAA) patients.
  
  
  RESULTS
  The prevalence of HAAA among cases of SAA was 4.34% (41/944). The proportion of VSAA in HAAA cases was significantly higher than IAA (65.9% vs 39.4%, P=0.001). There was no significant difference in the prevalence of hemorrhage and infections between HAAA and IAA patients, but the duration of infection persistence in HAAA group was much longer than IAA group [21 (4-100) d vs 13 (3-139) d, P=0.048]. The absolute counts of CD3(+) T-cell, CD3(+)CD4(+)T-cell, CD3(+)CD8(+)T-cell and ratio of CD4(+) T-cell/CD8(+) T-cell in HAAA were significant lower than that in IAA patients. However, the percentage of CD3(+)CD8(+)T-cell in HAAA was significant higher than that in IAA (P <0.05). The total response in HAAA and IAA patients treated with IST were 34.1% vs 34.1% (P=1.000), 56.1% vs 53.7% (P=0.787), and 73.2% vs 68.3% (P=0.558) at 3, 6, 12 months after IST, respectively. There were no significant difference in 5-year overall survival and event-free survival between HAAA and IAA patients (90% vs 87.1%, P=0.700; 71.9% vs 62.4%, P=0.450).
  
  
  CONCLUSIONS
  HAAA was a rare distinct variant of aplastic anemia with more severe bone marrow failure and more severe imbalance of the T cell immune system than IAA. Treatment outcomes were comparable in patients with HAAA and IAA.
authors.affiliation: Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China.
authors.forename: W R
authors.initials: WR
authors.lastname: Yang
authors.forename: L P
authors.initials: LP
authors.lastname: Jing
authors.forename: K
authors.initials: K
authors.lastname: Zhou
authors.forename: G X
authors.initials: GX
authors.lastname: Peng
authors.forename: Y
authors.initials: Y
authors.lastname: Li
authors.forename: L
authors.initials: L
authors.lastname: Ye
authors.forename: Y
authors.initials: Y
authors.lastname: Li
authors.forename: J P
authors.initials: JP
authors.lastname: Li
authors.forename: H H
authors.initials: HH
authors.lastname: Fan
authors.forename: L
authors.initials: L
authors.lastname: Song
authors.forename: X
authors.initials: X
authors.lastname: Zhao
authors.forename: Y
authors.initials: Y
authors.lastname: Yang
authors.forename: F K
authors.initials: FK
authors.lastname: Zhang
authors.forename: L
authors.initials: L
authors.lastname: Zhang
mesh_terms: D000741:Anemia, Aplastic / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D018572:Disease-Free Survival; D006505:Hepatitis / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D010198:Pancytopenia / Q000150:complications; D012189:Retrospective Studies; D016176:T-Lymphocyte Subsets / Q000166:cytology; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents